- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00420888
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
30 juin 2015 mis à jour par: Active Biotech AB
A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.
The drug ABR-217620/naptumomab estafenatox is a fusion of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system.
This results in an accumulation of white blood cells in the cancer that can fight the cancer.
This study will compare the safety and effectiveness (assessed by tumor status and survival) of ABR-217620/naptumomab estafenatox when given with standard therapy IFN-alpha to IFN-alpha alone in patients with advanced renal cell carcinoma (RCC).
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
526
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Pleven, Bulgarie, 5800
- Department of Chemotherapy, University General Hospital for Active Treatment "Georgi Stranski"
-
Plovdiv, Bulgarie, 4004
- 1st Internal Department District Dispensary for Cancer Diseases with Inpatient Hospital
-
Sofia, Bulgarie, 1431
- Multifile Hospital "Aleksandrovska", Urology Clinic, Department of Oncourology
-
Sofia, Bulgarie, 1527
- Oncology Clinic, University General Hospital for Active Treatment "Tzaritza Yoanna"
-
Varna, Bulgarie, 9002
- Urology Clinic, General Hospital for Active Treatment "St. Anna"
-
Veliko Tarnovo, Bulgarie, 5000
- Department of Chemotherapy, Inter-district Dispensary for Cancer Diseases with Inpatient Hospital
-
-
-
-
-
Arkhangelsk, Fédération Russe
- Arkhangelsk Regional Oncology Center
-
Chelyabinsk, Fédération Russe, 454087
- Chelyabinsk Regional Oncology Center
-
Kazan, Fédération Russe, 420029
- Republican Clinical Oncology Center
-
Kazan, Fédération Russe, 420111
- Kazan City Oncology Center
-
Moscow, Fédération Russe, 115478
- Russian Oncological Research Center n.a. N.N. Blokhin
-
Moscow, Fédération Russe, 105425
- Research Institute of Urology
-
Moscow, Fédération Russe, 117997
- Russian Research Center of Radiology
-
Obninsk, Fédération Russe, 249036
- Medical Radiology Research Center
-
Orenburg, Fédération Russe, 460021
- Orenburg Regional Clinical Oncology Center
-
St. Petersburg, Fédération Russe, 191104
- Leningrad Regional Oncological Center
-
St. Petersburg, Fédération Russe, 193312
- Municipal Aleksandrovskaya Hospital
-
St. Petersburg, Fédération Russe, 194354
- Municipal Multi-Speciality Hospital #2
-
St. Petersburg, Fédération Russe, 196247
- Municipal Hospital #26
-
St. Petersburg, Fédération Russe, 197022
- Municipal Clinical Oncology Center
-
St. Petersburg, Fédération Russe, 197758
- Central Research Institute of Roentgenology and Radiology
-
St. Petersburg, Fédération Russe, 197758
- Research Institute of Oncology n.a. Professor N.N. Petrov
-
St. Petersburg, Fédération Russe, 198205
- Municipal Hospital #15
-
Stavropol, Fédération Russe, 355047
- Stavropol Territorial Clinical Oncology Center
-
Yaroslavl, Fédération Russe, 150054
- Regional Clinical Oncology Hospital
-
-
-
-
-
Bucharest, Roumanie, 022328
- Fundeni Clinical Institute - Urology Department
-
Bucharest, Roumanie, 041345
- Dinu Uromedica
-
Bucharest, Roumanie, 050659
- "Prof. Dr. Th. Burghele" Clinical Hospital, Urology Clinic
-
Cluj Napoca, Roumanie, 400015
- "I. Chiricuta" Institute of Oncology
-
Cluj Napoca, Roumanie, 400016
- E-URO Medical Center
-
Constanta, Roumanie, 900635
- Provita Center SRL
-
Sibiu, Roumanie, 550245
- Sibiu Clinical Country Hospital - Urology Clinic
-
Timisoara, Roumanie, 300239
- Oncomed SRL
-
-
-
-
-
Cambridge, Royaume-Uni, CB2 0QQ
- Addenbrooke's Hospital, Cambridge Clinical Trials Centre
-
Derby, Royaume-Uni, DE1 2QY
- Derby Hospital NHS Trust
-
Glasgow, Royaume-Uni, G12 0YN
- The Beatson West of Scotland Cancer Centre
-
Leeds, Royaume-Uni, LS9 7TF
- St. James's Institute of Oncology
-
London, Royaume-Uni, SW6 6JJ
- The Royal Marsden NHS Trust
-
Manchester, Royaume-Uni, M20 4BX
- The Christie Hospital NHS Trust
-
Swansea, Royaume-Uni, SA2 8QA
- South Wales Cancer Institute, Singleton Hospital
-
-
-
-
-
Cherkassy, Ukraine, 18009
- Cherkassy Regional Oncology Center
-
Chernigov, Ukraine, 14029
- Chernigov Regional Oncology Center
-
Dnepropetrovsk, Ukraine, 49005
- Urology Department, Dnepropetrovsk State Medical Academy
-
Dnepropetrovsk, Ukraine, 49102
- City General Hospital #4
-
Donetsk, Ukraine, 83092
- Donetsk Regional Antitumor Center
-
Ivano-Frankovsk, Ukraine, 76000
- Ivano-Frankovsk Regional Oncology Center
-
Kharkiv, Ukraine, 61037
- Kharkiv Regional Urology and Nephrology Center
-
Kiev, Ukraine, 04053
- Institute of Urology under the Academy of Medical Sciences of Ukraine, Department of Plastic and Supportive Urology
-
Kiev, Ukraine, 04053
- Institute of Urology under the Academy of Medical Sciences of Ukraine, Urology Department
-
Lvov, Ukraine, 79031
- State Regional Diagnostics and Treatment Oncology Center
-
Uzhorod, Ukraine, 88014
- Regional Oncology Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Histologically or cytologically confirmed RCC (clear cell and papillary types)
- Metastatic or inoperable locally advanced RCC
- Eligible for therapy with IFN-alpha.
- Measurable disease defined by at least 1 measurable lesion on CT scan (lesion diameter greater than or equal to 2.0 cm by a standard CT scanner or greater than or equal to 1.0 cm by a spiral CT scanner)
- Favorable or moderate risk group prognosis by MSKCC (Motzer) criteria (score 0-2)
- Karnofsky performance status greater than or equal to 70
- Age greater than or equal to 18
- Life expectancy greater than 3 months
Baseline blood counts:
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
- Platelets greater than or equal to 100 x 10^9/L
- Haemoglobin greater than or equal to 100 g/L
Baseline blood chemistry levels:
- Creatinine less than or equal to 1.5 x upper limit of normal (ULN)
- Bilirubin less than or equal to 2 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN. AST and ALT allowed less than or equal to 5 x ULN for patients with liver metastases.
- If fertile, patient will use effective method of contraception throughout the study
- Willing and able to comply with the treatment and follow-up visits and examinations
- Capable of understanding the parameters in the protocol and able to sign a written consent form
Exclusion Criteria:
- Pregnant or breastfeeding women
- Serious uncontrolled medical disorder or active infection ongoing or resolved within 2 weeks before first dose of study drug and that the investigator believes would impair the patient's ability to receive study drug
- History of malignancy within 5 years or concurrent malignancy, except successfully treated non-melanoma skin cancer, cervical cancer in situ, ductal carcinoma in situ or lobular carcinoma in situ of breast may be included
- History and/or signs of parenchymal brain metastases
- Significant cardiac disease including: history (within 6 months) or current unstable angina pectoris, congestive heart failure (NYHA stage III-IV), myocardial infarction within 12 months, or uncontrolled arterial hypertension.
- History of stroke within 5 years and/or transient ischemic attack within 6 months.
- Acute illness or evidence of infection, including unexplained fever (>100.5ºF or 38.1ºC) within 2 weeks before start of treatment
- Treatment with biological response modifiers within 3 weeks prior to the start of treatment and up to the End-of-Study visit
- Treatment with beta-blockers, including topical therapy for glaucoma, within 5 days before start of treatment and during the 4-day ABR-217620/naptumomab estafenatox treatment
- Treatment with systemic corticosteroids within 2 weeks before start of treatment or likely need for such treatment during the study
- Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis
- Known positive serology for HIV
- Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known virus carrying; patients who recovered from Hepatitis A are allowed
- Treatment with anticoagulants within 2 weeks before start of treatment, except when used to maintain the patency of a central or peripheral venous line
- Radiotherapy less than 4 weeks before start of treatment
- Major surgery or tumor embolization less than 4 weeks before start of treatment
- Previous exposure to murine monoclonal antibodies or known hypersensitivity to murine proteins
- Currently on renal dialysis treatment
- Known allergy or hypersensitivity to aminoglycosides and kanamycin
- Previous systemic anti-tumor therapy for RCC (including immunotherapy with IFN-alpha or IL-2 or any chemotherapy) except sunitinib or other oral antiangiogenic therapy
- Participation in any study with investigational drugs for RCC within 6 weeks
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 1
|
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Autres noms:
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Autres noms:
|
|
Expérimental: Safety group
6-12 patients
|
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Autres noms:
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Autres noms:
|
|
Autre: 2
Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
|
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Time to death
Délai: every 12 weeks, including after a maximum of 18 months of study treatment
|
every 12 weeks, including after a maximum of 18 months of study treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Progression-free survival time
Délai: every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period
|
every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period
|
|
Objective tumor response rate
Délai: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Best overall response
Délai: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Duration of response
Délai: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Changes in sum of target lesions
Délai: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Immunological response in patients on combined treatment of ABR-217620/naptumomab estafenatox and IFN-alpha
Délai: Weeks 1, 9, 17, 25, 73
|
Weeks 1, 9, 17, 25, 73
|
|
Vital signs
Délai: every visit through Week 25, plus Week 73
|
every visit through Week 25, plus Week 73
|
|
Physical measurements
Délai: Weeks 1, 9, 17, 25, 73
|
Weeks 1, 9, 17, 25, 73
|
|
Adverse events
Délai: every visit through Week 73
|
every visit through Week 73
|
|
Laboratory safety assessments
Délai: Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73
|
Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73
|
|
Pharmacokinetic parameters of ABR-217620/naptumomab estafenatox
Délai: Weeks 1, 9, and 17
|
Weeks 1, 9, and 17
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: Thore Nederman, PhD, Active Biotech AB
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle O, Eisen T. A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNalpha versus IFNalpha in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clin Cancer Res. 2016 Jul 1;22(13):3172-81. doi: 10.1158/1078-0432.CCR-15-0580. Epub 2016 Feb 5.
- Eisen T, Hedlund G, Forsberg G, Nordle Ö, Hawkins R. Baseline biomarker trend analysis of a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α vs IFN-α in advanced renal cell carcinoma. European Cancer Congress (ECCO) 2013; Abstract ID: 2710.
- Elkord E, Burt DJ, Sundstedt A, Nordle O, Hedlund G, Hawkins RE. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-alpha versus IFN-alpha. Oncotarget. 2015 Feb 28;6(6):4428-39. doi: 10.18632/oncotarget.2922.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 janvier 2007
Achèvement primaire (Réel)
1 janvier 2013
Achèvement de l'étude (Réel)
1 janvier 2013
Dates d'inscription aux études
Première soumission
9 janvier 2007
Première soumission répondant aux critères de contrôle qualité
9 janvier 2007
Première publication (Estimation)
11 janvier 2007
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
22 juillet 2015
Dernière mise à jour soumise répondant aux critères de contrôle qualité
30 juin 2015
Dernière vérification
1 juin 2014
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs urologiques
- Tumeurs urogénitales
- Tumeurs par site
- Maladies rénales
- Maladies urologiques
- Adénocarcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs rénales
- Carcinome à cellules rénales
- Carcinome
- Effets physiologiques des médicaments
- Facteurs immunologiques
- Anticorps monoclonaux
- Immunoconjugués
Autres numéros d'identification d'étude
- 06762004
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .